{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '4. Treatment Plan', '4.1. Study Design', 'This is an open label, multi-site, Phase II study designed to determine the', 'negative repeat prostate biopsy rate following 90-days of treatment with apalutamide.', 'All subjects must be enrolled in the active surveillance program at the University of', 'Washington Medical Center. All eligible patients will initiate therapy with apalutamide,', 'which will be administered at the FDA approved dose for treating non-metastatic', 'castration-resistant prostate cancer (i.e., 240 mg daily by mouth). Note that', 'apalutamide is FDA approved only for the treatment of patients with non-metastatic', 'castration-resistant prostate cancer, and is under development as an investigational', 'product for other types of prostate cancer. Subjects will have either 1) an MRI', 'detectable cancer of PIRADS 3 or more >5mm, and pathologically documented by', 'MRI/TRUS fusion biopsy with coordinates of biopsy site stored for repeat biopsy; or 2) a', 'systematic 12 core biopsy pathologically documenting prostate cancer with the', 'coordinates of the biopsy sites stored for repeat biopsy. This biopsy may be done up to', '12-months prior to enrollment.', 'Following 90-days of treatment with apalutamide, patients will undergo a repeat', 'prostate biopsy selectively targeting sites of prior positive biopsies (3 from each positive', 'biopsy site) plus a 12 core systematic prostate biopsy without targeting. All patients will', 'continue on active surveillance per the standard practice of the treating urologist.', 'Must meet one of the following criteria:', '1) Very low-risk prostate cancer:', '.', 'Stage T1c', '. PSA density <0.15 ng/mL', '. Gleason 6', '<2 cores with <50% involvement of any core,', '1) Selective site', 'or any percent involvement if unilateral', 'directed biopsy', 'disease', '(3 cores per site)', 'ARN-509 240 mg daily', 'Determine negative', '2) Low risk prostate cancer:', 'Treatment: 90 days', 'And', 'repeat biopsy rate', '. Stage <T2a', 'PSA <15 ng/mL', '2) Systematic 12', '. Gleason 6', 'core biopsy', '3) Low-intermediate risk prostate cancer', '. Stage T1c', '.', 'PSA <15 ng/mL', '. Gleason 3+4 in <50% of one core', '.', 'Gleason 6 in all other cores', 'Figure 3: Study scheme.', '32', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'The primary endpoint for this trial will be the absence of residual carcinoma (i.e. a', 'negative repeat biopsy) as determined by targeted and systematic biopsies following', '90-days of apalutamide. Secondary endpoints will include: exit from active surveillance', 'due to pathologic progression or otherwise at 2 years, receipt of local treatment for', 'prostate cancer at 2 years, local treatment free survival, PSA progression at 2 years,', 'PSA PFS as defined by Prostate Cancer Working Group 2 (PCWG2) criteria,', 'radiographic disappearance of MRI detectable nodules following treatment, quality of', 'life changes and safety (as assessed by the revised National Cancer Institute Common', 'Terminology Criteria for Adverse Events [NCI CTCAE], version 4.03). 1', 'Biopsy specimens, blood and plasma samples will be stored at -80\u00b0C. These', 'specimens will be labeled with a subjects unique study ID, and will not have personal', 'identifiers imprinted on them. Samples (i.e., prostate tissue, blood, and plasma) will be', 'obtained pre- and post-treatment with apalutamide. These biologic specimens will be', 'used for additional correlative work. Examples of studies to be conducted may include,', 'but are not limited to: assessment for PTEN loss via immunohistochemistry (IHC),', 'assessment for alteration in MYC/chromosome 8q24 via FISH and tumor mRNA', 'expression profiling/risk classification (e.g., Decipher [GenomeDX Biosciences, San', 'Diego, CA], Oncotype DX Prostate Cancer Assay [Genomic Health, Inc., Redwood City,', 'CA], or RNA-seq). 2-6', 'Subject enrollment requires a baseline systematic 12 core biopsy with pathologically', 'documented prostate cancer and with the coordinates of the biopsy sites stored for', 'repeat biopsy. Subjects can include men with newly diagnosed prostate cancer or those', 'already enrolled in active surveillance, but baseline prostate biopsy must have occurred', 'within 12-months of enrolling onto this study. Subjects may have had a multiparametric', 'MRI of the prostate performed at least 6 months from any prior prostate biopsy. If an', 'MRI detectable cancer of PIRADS 3 or more and >5mm was pathologically', 'documented by MRI/TRUS fusion biopsy with coordinates of biopsy site stored, this', 'lesion will be targeted for repeat biopsy. Otherwise, coordinates should be stored using', 'a standard sextant prostate biopsy diagram (Appendix A) to aid in targeted repeat', 'biopsy. Ninety days after treatment with apalutamide, all subjects will undergo 1)', 'selective biopsy targeting cancer positive sites based on stored coordinates (3 biopsy', 'cores per positive site); and 2) a 12 core non targeted systematic biopsy. PSA will be', '33', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}